Siemens Healthineers and Novo collaborate to expand non-invasive blood-based testing for MASLD and MASH. Learn about this healthcare partnership.

Caliway's CBL-514 shows positive Phase II results for Dercum's disease, offering the first targeted treatment option. Statistically significant ...

Otsuka's ulefnersen becomes first drug to meet primary endpoint in placebo-controlled FUS-ALS trial, targeting rare genetic ...

Celldex reports positive Phase 3 results for barzolvolimab in chronic urticaria, meeting primary endpoints. Read the ...

FDA Fast Track designation for QRX003, a first-in-class treatment for peeling skin syndrome. Quoin Pharmaceuticals advances ...

Viking's VK2735 sustains 97% weight loss with monthly injections. Discover how this GLP-1/GIP agonist offers flexible ...

European Commission approves Trixeo Aerosphere, the first triple-combination inhaler for inadequately controlled asthma in patients 12+. Learn more now.

Roche's sefaxersen achieves Phase III primary endpoint in IgA nephropathy trial with significant proteinuria reductions. Read the latest biotech breakthrough.

Waltham, Massachusetts-based Pretzel Therapeutics announced receipt of US FDA Fast Track Designation for PX578, a central nervous system-penetrant small molecule activator of mitochondrial DNA ...

Grünenthal expands into oncology with EUR 375M acquisition of Stivarga from Bayer. Strategic deal for regorafenib cancer treatment rights. Read more.

Longeveron's laromestrocel failed to improve heart function in HLHS infants. Read the ELPIS II trial results and what's next for the biotech company.

AI oncology firm Iambic Therapeutics files S-1 for Nasdaq IPO backed by $1.7B in Big Pharma partnerships. Read the latest biotech IPO news.